Cascade Prodrug Overview
- Founded
-
2009
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$450K
- Investors
-
14
Cascade Prodrug General Information
Description
Developer of chemotherapy technology designed to treat a variety of solid tumor indications. The company's technology specializes in the advantage of tumor hypoxia and triggers drug conversion in the tumor where it's needed, thus limiting the exposure of healthy tissue to a potent cytotoxic agent, enabling cancer patients to experience an improved safety profile relative to currently approved chemotherapy agents.
Contact Information
Website
www.cascadeprodrug.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Biotechnology
Primary Office
- Post Office Box 13020
- Eugene, OR 97440
- United States
+1 (541) 000-0000
Cascade Prodrug Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 06-Apr-2020 | $450K | 00.000 | Completed | Generating Revenue | |
| 6. Later Stage VC | 03-Jun-2016 | 00000 | 00.000 | Completed | Generating Revenue | |
| 5. Later Stage VC | 03-Apr-2015 | 0000 | 00.000 | Completed | Generating Revenue | |
| 4. Early Stage VC (Series A) | 01-Apr-2013 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 3. Grant | 11-May-2012 | 00000 | 00000 | Completed | Generating Revenue | |
| 2. Early Stage VC | 14-Feb-2012 | $400K | $400K | Completed | Generating Revenue | |
| 1. Grant | 29-Oct-2010 | $244K | Completed | Generating Revenue |
Cascade Prodrug Patents
Cascade Prodrug Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2681222-A1 | Mannich base n-oxide drugs | Active | 19-Mar-2007 | 0000000000 | |
| CA-2681222-C | Mannich base n-oxide drugs | Active | 19-Mar-2007 | 0000000000 | |
| EP-2136626-A4 | Mannich base n-oxide drugs | Inactive | 19-Mar-2007 | 0000000000 | 0 |
| EP-2136626-A1 | Mannich base n-oxide drugs | Inactive | 19-Mar-2007 | 0000000000 | |
| US-20100016252-A1 | Mannich base n-oxide drugs | Active | 19-Mar-2007 | C07C291/04 |
Cascade Prodrug Executive Team (4)
Cascade Prodrug Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Allan Cochrane | Cascade Prodrug | Co-Founder, President, Board Member & Head of Corporate Development | 000 0000 |
| Armen Shanafelt Ph.D | Self | Board Member | 000 0000 |
| August Sick | Cascade Prodrug | Co-Founder, Managing Director & Board Member | 000 0000 |
| Eric Malek | Cascade Prodrug | Chief Business Officer & Board Member | 000 0000 |
| Lynnor Stevenson Ph.D | Oregon Venture Fund | Board Member | 000 0000 |
Cascade Prodrug Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Cascade Prodrug Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Elevate Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Elijahu Shapira | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Eric Boothe | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Eric Doebele | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Justin Curzi | Angel (individual) | Minority | 000 0000 | 000000 0 |